on ONXEO (EPA:ALONX)
Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates
Valerio Therapeutics S.A. has announced its financial results for the first half of 2024. Key highlights include the acquisition of Emglev Therapeutics, aimed at advancing their single-domain antibodies (sdAbs) technology. The VIO-01 trial is progressing through Phase 1 dose escalation, exploring its potential as a new anti-cancer treatment.
The company reported no consolidated revenues for the period ending June 30, 2024. Operating expenses decreased to €10.8 million from €11.6 million in the first half of 2023. The net loss was €11 million, improved slightly from €11.6 million in the previous year.
Valerio's cash balance stood at €4 million as of June 30, 2024. The company is leveraging shareholder loans and Research Tax Credits to maintain financial visibility through the end of the year.
In addition to financial updates, Valerio continues to optimize its PlatON™ platform and develop VIO-01 through dose escalation in clinical trials. The company remains committed to creating value through its innovative oncology drug pipeline.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONXEO news